Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 3
1994 2
1995 1
1996 1
1997 1
1998 1
1999 2
2001 1
2002 1
2003 1
2006 1
2007 2
2011 2
2012 4
2013 2
2014 1
2015 1
2016 1
2017 2
2020 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains.
Fabeni L, Berno G, Fokam J, Bertoli A, Alteri C, Gori C, Forbici F, Takou D, Vergori A, Zaccarelli M, Maffongelli G, Borghi V, Latini A, Pennica A, Mastroianni CM, Montella F, Mussini C, Andreoni M, Antinori A, Perno CF, Santoro MM; Resistance Study Group. Fabeni L, et al. J Clin Microbiol. 2017 Sep;55(9):2827-2837. doi: 10.1128/JCM.00656-17. Epub 2017 Jul 12. J Clin Microbiol. 2017. PMID: 28701420 Free PMC article.
Real word outcomes associated with use of raltegravir in older people living with HIV: results from the 60 months follow-up of the RAL-age cohort.
Santinelli L, Ceccarelli G, Borrazzo C, Celani L, Pavone P, Innocenti GP, Spagnolello O, Fimiani C, Ceci F, Di Sora F, Mezzaroma I, Mastroianni CM, d'Ettorre G. Santinelli L, et al. Among authors: di sora f. Expert Rev Anti Infect Ther. 2020 May;18(5):485-492. doi: 10.1080/14787210.2020.1733415. Epub 2020 Feb 25. Expert Rev Anti Infect Ther. 2020. PMID: 32096433
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21.
Fabeni L, Armenia D, Abbate I, Gagliardini R, Mazzotta V, Bertoli A, Gennari W, Forbici F, Berno G, Piermatteo L, Borghi V, Pinnetti C, Vergori A, Mondi A, Parruti G, Di Sora F, Iannetta M, Lichtner M, Latini A, Mussini C, Sarmati L, Perno CF, Girardi E, Antinori A, Ceccherini-Silberstein F, Maggi F, Santoro MM; Italian HIV Drug Resistance Group. Fabeni L, et al. Among authors: di sora f. J Antimicrob Chemother. 2024 Sep 3;79(9):2152-2162. doi: 10.1093/jac/dkae189. J Antimicrob Chemother. 2024. PMID: 39028674 Free PMC article.
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.
Galli L, Spagnuolo V, Bigoloni A, D'Arminio Monforte A, Montella F, Antinori A, Di Biagio A, Rusconi S, Guaraldi G, Di Giambenedetto S, Borderi M, Gibellini D, Caramatti G, Lazzarin A, Castagna A; MODAt Study Group. Galli L, et al. J Antimicrob Chemother. 2016 Jun;71(6):1637-42. doi: 10.1093/jac/dkw031. Epub 2016 Mar 5. J Antimicrob Chemother. 2016. PMID: 26945711 Clinical Trial.
Combined immediate- and delayed-type hypersensitivity to metamizole.
Bellegrandi S, Rosso R, Mattiacci G, Zaffiro A, Di Sora F, Menzella F, Aiuti F, Paganelli R. Bellegrandi S, et al. Among authors: di sora f. Allergy. 1999 Jan;54(1):88-90. doi: 10.1034/j.1398-9995.1999.00953.x. Allergy. 1999. PMID: 10195371 No abstract available.
31 results